Clinical Trials Arena on MSN2d
ViiV to trial twice-yearly HIV antibody dosing after Phase IIb successThe company’s Phase IIb trial found the therapy, N6LS, was able to maintain viral loads below a detectable threshold.
To cut out this virus, the team used CRISPR-Cas gene ... managing to completely inactivate HIV with a single guide RNA and ...
The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...
The device demonstrated a detection limit of 30 copies/mL of HIV RNA, a level comparable to traditional laboratory methods, with no cross-reactivity to hepatitis C virus (HCV). Clinical testing ...
To become infectious, HIV has to undergo a maturation process, which involves a rearrangement of the matrix proteins (red). In an immature virus particle, the matrix proteins form a lose lattice ...
What about viruses? Would you consider them living or nonliving? Let’s look closely at the life cycle of the human immunodeficiency virus (HIV) – the virus that causes AIDS – to find out. This ...
Results show similar levels of virus undetectability in patients on ibalizumab-containing regimens as in controls, despite greater baseline ...
The presence of anti-CD4 autoantibodies in treatment-naive patients with advanced HIV was associated with a decreased rate of CD4 reconstitution following ART initiation.
Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback